Kourie Hampig Raphael, Awada Gil, Awada Ahmad
Department of Oncology, Faculty of medicine, Saint Joseph University, Beirut, Lebanon.
Medical Oncology clinic, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.
Immunotherapy. 2017 Jun;9(8):647-657. doi: 10.2217/imt-2017-0029.
After the first wave of the tsunami of immune checkpoint inhibitors, 2016 was marked by the second wave, revealed by numerous US FDA approvals, publications and abstracts in relation with these drugs in different cancers and settings. First, we reported all new indications of anti-CTLA4, anti-programmed cell death protein 1 and anti-PDL1 approved by the FDA, the positive clinical trials published and the abstracts reported at important scientific meetings during 2016. Then, we highlighted the updates on debatable issues related to checkpoint inhibitors, since the first wave published in a previous issue. We focused on the predictive biomarkers, combination therapies, tumor response patterns and efficacy in particular settings and the side effect management. Finally, the impact of checkpoint inhibitors development on the care management of cancer centers will be discussed.
在免疫检查点抑制剂的第一波热潮之后，2016年迎来了第二波热潮，这体现在美国食品药品监督管理局（US FDA）对这些药物在不同癌症及治疗场景下的大量批准、相关出版物及摘要中。首先，我们报道了2016年美国食品药品监督管理局批准的抗CTLA4、抗程序性细胞死亡蛋白1及抗PDL1的所有新适应症、已发表的阳性临床试验以及在重要科学会议上报道的摘要。然后，自上一期发表第一波热潮以来，我们着重介绍了与检查点抑制剂相关的争议问题的最新进展。我们特别关注预测性生物标志物、联合疗法、肿瘤反应模式、特定场景下的疗效以及副作用管理。最后，将讨论检查点抑制剂的研发对癌症中心护理管理的影响。
